CSL Seqirus

Seqirus (NZ) Limited
L3, 60 Parnell Road, Parnell, Auckland 1052, New Zealand
T: 0800 502 757

CSL.com
CSLSeqirus.com

28 October 2024

Dear Healthcare Professional,

Important information: Ferinject (ferric carboxymaltose) 50 mg/mL solution for injection
INTERIM PACKAGING

This information is being sent in agreement with Medsafe.

To accommodate a temporary supply issue of Ferinject, CSL Seqirus (NZ) will also be supplying **Ferinject** Australian labelled stock for funded and private use.

The difference is the information provided in the package insert and the side panel of the carton label (as further detailed below).

Package Insert
The Australian labelled package insert has a different age indication to the New Zealand labelled stock.

The indication in the Australian Pack Insert reads as follows:

> FERINJECT is indicated for the treatment of iron deficiency in adults and adolescents aged 14 years and older when:
> - oral iron preparations are ineffective
> - oral iron preparations cannot be used
> - there is a clinical need to deliver iron rapidly

> The diagnosis of iron deficiency must be based on laboratory tests.

> FERINJECT is indicated for the treatment of iron deficiency anemia in children aged 1 to 13 years when:
> - oral iron preparations are ineffective
> - oral iron preparations cannot be used

> The diagnosis of iron deficiency anemia must be based on laboratory tests.

There is no specified age indication for Ferinject in New Zealand however, the New Zealand Data Sheet states in the Warnings and Precautions Section that the “use of Ferinject has not been studied in children and therefore is not recommended in children under 14 years”.

The Medsafe indication for Ferinject **remains the same:**

> FERINJECT is indicated for the treatment of iron deficiency when:
> - oral iron preparations are ineffective
> - oral iron preparations cannot be used
> - there is a clinical need to deliver iron rapidly

> The diagnosis must be based on laboratory tests.

Seqirus (NZ) Limited
L3, 60 Parnell Road, Parnell, Auckland 1052, New Zealand
T: 0800 502 757

CSL.com
CSLSeqirus.com

All references to the use of Ferinject in patients aged 1 to 13 years currently included in Section 4.1 and 4.2 of the Package Insert should be disregarded. Patients should use the New Zealand approved Data Sheet which is available via the Medsafe website: https://www.medsafe.govt.nz/profs/Datasheet/f/ferinjectinj.pdf

Carton label

The Australia carton label currently does not include the New Zealand distributor details. For clarity, the carton label panel of the current New Zealand and Australian products is provided below.

New Zealand label	Australian label
	

*All other aspects of the carton label are identical.

If you have any queries or would like further information, please contact CSL Seqirus Medical Information NZ via aunz.medicalinformation@seqirus.com or phone 0800 502 757. Any information regarding adverse event reporting should continue to be reported to Medsafe via the following link: https://pophealth.my.site.com/carmreportnz/s/

Edith Rosenberg MSc (Hons) Pharmacology
HEAD OF MEDICAL AFFAIRS NZ

FERINJECT® (ferric carboxymaltose) solution for intravenous (IV) use, for the treatment of iron deficiency when oral iron preparations are ineffective, cannot be used, or there is a clinical need to deliver iron rapidly. FERINJECT is listed on the HML and is a funded Prescription Medicine – special authority criteria apply. Before prescribing FERINJECT please review the Data Sheet (07/2024) for information on dosage, contraindications, precautions, interactions and adverse effects, available at www.medsafe.govt.nz. FERINJECT® is a registered trademark of Vifor Pharma Group distributed by CSL Seqirus (Auckland) New Zealand, 0800 502 757
NZ-FERI-24-0037; TAPS DA2414ER